| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| エンジバント社(現 スミトモファーマ・アメリカ社) | ||||||||
| オルゴビクス | ||||||||
|
|
||||||||
| ジェムテサ | ||||||||
|
|
||||||||
|
|
||||||||
| ポクセル社 | ||||||||
| マイフェンブリー | ||||||||
| メディシン・フォー・マラリア・ベンチャー(MMV) | ||||||||
|
|
||||||||
| 京都大学iPS 細胞研究所 | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| 医薬基盤・健康・栄養研究所 | ||||||||
|
|
||||||||
| 愛媛大学等 | ||||||||
| Keio University | ||||||||
| 東京慈恵会医科大学 | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| 神戸アイセンター病院 |
In 1897, Osaka Pharmaceutical Co., Ltd. was established by 21 prominent pharmaceutical families in Osaka's Michishio-cho
Established a pharmaceutical plant in Ebieda, Osaka (formerly Osaka Factory, former Osaka Comprehensive Center)
Absorbed and merged with the semi-government, semi-private Dai Nippon Pharmaceutical Company in Tokyo, renaming the company to Dai Nippon Pharmaceutical Co., Ltd.
Establishment of pharmaceutical plant in Osaka's Ebira (former Osaka plant, former Osaka Comprehensive Center); absorption of semi-public, semi-private Dai Nippon Pharmaceutical Company in Tokyo and renaming to Dai Nippon Pharmaceutical Co., Ltd.
Absorbed and merged Osaka Pharmaceutical Testing Co., Ltd.
Started the chemical products business
Start of the chemical products business
Newly launched the bronchodilator and cough suppressant "Ephedrine 'Nagawi®'"
New release of bronchodilator and cough suppressant "Ephedrine 'Nagawari®'"
Sumitomo Chemical Industry Co., Ltd. (now Sumitomo Chemical Co., Ltd.) entered the pharmaceutical business
1944: Sumitomo Chemical Industry Co., Ltd. (now Sumitomo Chemical Co., Ltd.) entered the pharmaceutical business
Started the veterinary drug business
Start of the veterinary drugs business
Started the general medicine business
Start of the over-the-counter pharmaceutical business
Started the food additive business
Start of the food additive business
Sumitomo Chemical Industry Co., Ltd. launched chloroquine formulation (Kininon)
1961: Sumitomo Chemical Industry Co., Ltd. launched chloroquine formulation (Kininon). For information on the chloroquine drug injury case, see: Sustainability "Reliability Assurance"
1961: Sumitomo Chemical Industries Co., Ltd. released chloroquine formulation (Kininon)
Self-recalled the thalidomide formulation (Isomin released in 1958, Provan M released in 1960)
Self-recall of thalidomide preparations (Isomin released in 1958, Provan M released in 1960)
Established Dai Nippon Pharmaceutical in Taiwan
Establishment of Taiwan Dai Nippon Pharmaceutical
Established the Suzuka plant in Suzuka City, Mie Prefecture
Establishment of Suzuka plant (Suzuka City, Mie Prefecture)
Completed the Comprehensive Research Institute in Suita City, Osaka Prefecture
Completion of Comprehensive Research Institute (Saitama City, Osaka Prefecture)
Started the Laboratory Products business
Start of the Laboratory Products business
Newly launched the antibacterial chemotherapy agent "Dulcol®"
New release of antibacterial chemotherapy agent "Dulcol®"
Sumitomo Chemical Industry Co., Ltd. inherited the research, development, and manufacturing divisions of its pharmaceutical business and the pharmaceutical sales division of Inabata Sangyo Co., Ltd., which had been the sole distributor of Sumitomo Chemical’s drugs, and in February 1984 Sumitomo Pharmaceutical Co., Ltd. was established, commencing operations on October 1 of the same year
1984: Established on February 6, 1984 (Showa 59): Sumitomo Chemical Industry Co., Ltd.'s pharmaceutical research, development, and manufacturing division and the pharmaceutical sales division of Inabata Industries Co., Ltd., which had been the sole distributor of Sumitomo Chemical's pharmaceuticals, were inherited. Sumitomo Pharma Co., Ltd. was established in February 1984 and began operations on October 1, 1984. New launch of transdermal analgesic anti-inflammatory cream "Inteban® Cream" and new launch of cephalosporin antibiotic "Sepatren®"
Sumitomo Pharma Co., Ltd. was established by inheriting the research, development, and manufacturing division of the pharmaceutical business of Sumitomo Chemical Industries Co., Ltd. and the pharmaceutical sales division of Inabata Sangyo Co., Ltd., which had been the sole distributor of Sumitomo Chemical's pharmaceuticals
Established February 6, 1984 (Showa 59): Sumitomo Chemical Industries Co., Ltd. inherited its pharmaceutical research, development, and manufacturing division, and inherited the pharmaceutical sales division of Inabata Sangyo Co., Ltd., which had been the sole distributor of Sumitomo Chemical’s drugs. Sumitomo Pharma Co., Ltd. was established in February 1984 and began operations on October 1 of the same year: New release of transdermal analgesic anti‑inflammatory cream "Inteban® Cream": New release of cephalosporin antibiotic formulation "Sepatren®"
Sumitomo Pharmaceutical Co., Ltd. commenced operations
Completion of Ehime Bio Plant
New launch of antihypertensive, angina, and arrhythmia drug "Almar® tablets"
1985: Completion of Ehime Bio Plant: New launch of antihypertensive, angina, and arrhythmia treatment drug "Almar® tablets"
Established the Epilepsy Treatment Research Promotion Foundation
New launch of natural interferon‑α formulation "Sumiferon®"
1987: New launch of natural interferon-α formulation "Sumiferon®"
Establishment of the Epilepsy Treatment Research Promotion Foundation
Opened a U.S. office
Newly launched the peripheral circulation improvement agent "Prolenar®"
Newly launched the sustained ACE inhibitor antihypertensive "Cetapril®"
Opening of the U.S. office, launch of the peripheral circulation improvement agent "Prolenal®", launch of the sustained ACE inhibitor antihypertensive "Cetapril®"
Establishment of U.S. office: New release of peripheral circulation improvement drug "Prolenal®": New release of long‑acting ACE inhibitor "Cetapril®"
New launch of antiepileptic drug "Exegran®"
New launch of norepinephrine‑acting neural function enhancer "Dopus®"
New release of antiepileptic "Exegran®"
1989: New launch of norepinephrine-acting neural function enhancer "Dopus®"
New release of bone metabolism enhancer "Daidroline®"
1990: New launch of bone metabolism enhancer "Daidronel®"
Completion of Osaka Product Center
1991: Osaka Commodity Center completed
Completion of the Central Logistics Center (currently Kobe Logistics Center)
Transfer of sales for feed additive business
New release of antihypertensive and angina medication "Amrojin®"
Completion of Central Logistics Center (now Kobe Logistics Center)
1993: Transfer of feed additive business: New launch of antihypertensive and angina treatment drug "Amrogin®"
New release of carbapenem antibiotic formulation "Melopen®"
1995: New launch of carbapenem antibiotic "Melopen®"
New launch of long‑acting antihistamine "Evastel®"
New release of serotonin-acting anxiolytic "Sedil®"
New release of sustained antihistamine "Evaster®"
1996: New launch of serotonin-acting anxiolytic "Sedil®"
Celebrating 100th anniversary of founding
Completion of new Tokyo Product Center (now Tokyo Logistics Center), establishment of Sumitomo Pharma UK Limited, opening of Beijing office
1997: Completion of new Tokyo Product Center (now Tokyo Logistics Center): Establishment of Sumitomo Pharma UK Limited and opening of Beijing office
100th anniversary of founding
Completion of the new Tokyo Product Center (now the Tokyo Logistics Center)
Establishment of Sumitomo Pharma UK Limited
Opening of the Beijing office
Opening offices in London and Beijing
New launch of gastrointestinal motility enhancer "Gasmotin®"
Opening of London and Beijing offices: New launch of gastrointestinal motility enhancer "Gasmotin®"
Opening of London and Beijing offices, launch of the gastrointestinal motility agent "Gasmotin®"
New launch of long‑acting cancer pain treatment "Kadian®"
New release of recombinant human growth hormone "Growject®", transfer of sales for animal drug business, establishment of Sumitomo Pharma America Limited
New launch of sustained-release cancer pain medication "Cadiann®"
1999: New launch of recombinant human growth hormone "Growject®"; Transfer of animal drug business: Establishment of Sumitomo Pharma America Limited
Launch of the recombinant natural human growth hormone "Growject®"
Transfer of animal drug business sales
Establishment of Sumitomo Pharma America Limited
Transfer of sales for active ingredient business, launch of disinfectant "Hibiten®"
2000: Transfer of raw material business: Commencement of sales of disinfectant "Hibitene®"
Transfer of active ingredient business sales
Launch of disinfectant "Hibiten®" sales
New release of antipsychotic "Ruran®", launch of H2 receptor antagonist "Tagamet®", start of sales for Sumitomo Pharma Biomedical Co., Ltd.
2001: New launch of antipsychotic "Ruran®"; Commencement of sales of H2 receptor antagonist "Tagamet®"; Commencement of operations of Sumitomo Pharma Biomedical Co., Ltd.
New release of antipsychotic "Ruran®"
Launch of H2 receptor antagonist "Tagamet®" sales
Start of sales for Sumitomo Pharma Biomedical Co., Ltd.
New launch of inhaled steroid asthma treatment "Cubarel™"
New launch of inhaled steroid asthma treatment "Cubar™"
Closure of Osaka plant and integration into Suzuka plant
New launch of oral cancer pain treatment solution "Opsu®"
Takeover of active ingredient manufacturing from Sumitomo Chemical, establishment of new Oita plant
Closure of Osaka plant (integrated into Suzuka plant): New launch of oral cancer pain medication "Opsu®"
Closure of Osaka plant (integrated into Suzuka plant), launch of the oral solution for cancer pain treatment "Opsu®"
2003: Took over active ingredient manufacturing from Sumitomo Chemical and established the Oita plant
20th anniversary of sales start
2004: 20th anniversary of operations
Transfer of sales of over‑the‑counter pharmaceutical business
New launch of long‑acting selective H1 antagonist "Evastel® OD tablets"
Transfer of general pharmaceutical business: New launch of sustained-release selective H1 antagonist "Evastel® OD tablets"
2005: Transfer of sales of the over-the-counter pharmaceutical business
Transfer of sales of the over-the-counter pharmaceutical business, launch of the sustained selective H1 receptor antagonist "Evastel® OD tablets"
Sumitomo Pharma was born in October 2005 through the merger of Dai Nippon Pharmaceutical Co., Ltd. and Sumitomo Pharma Co., Ltd.
Sumitomo Pharma was born in October 2005 from the merger of Dai Nippon Sankyo Co., Ltd. and Sumitomo Pharma Co., Ltd.
Born in October 2005 from the merger of Dai Nippon Sankyo Co., Ltd. and Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. published materials from its president's press conference and media briefing held on August 21, 2026. The materials contain information about pharmaceuticals and medical devices and are intended to disclose corporate information, not to promote products or provide medical advice.
Sumitomo Dainippon Pharma is advancing research and development aimed at clinical applications for refractory diseases in the field of regenerative and cellular medicine, with the goal of creating the world’s first therapeutic drug. This document introduces the company’s regenerative and cellular medicine business and the manufacturing of pharmaceuticals derived from iPS cells.